Adaptive Biotechnologies (ADPT) Total Liabilities (2018 - 2026)

Adaptive Biotechnologies has disclosed Total Liabilities across 9 years of filings, most recently posting $281.7 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $281.7 million, down 12.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $281.7 million (down 12.14% YoY), and the FY2025 annual result was $287.7 million, down 14.59% from the prior year.
• Total Liabilities came in at $281.7 million for Q1 2026 at Adaptive Biotechnologies, down from $287.7 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $396.4 million in Q3 2022 to a low of $281.7 million in Q1 2026.
• The 5-year median for Total Liabilities is $336.9 million (2024), against an average of $334.2 million.
• Across the five-year window, Total Liabilities slipped 15.22% in 2022 and advanced 27.84% in 2023, its largest moves.
• Adaptive Biotechnologies' Total Liabilities stood at $392.5 million in 2022, then fell by 10.1% to $352.9 million in 2023, then decreased by 4.52% to $336.9 million in 2024, then declined by 14.59% to $287.7 million in 2025, then dropped by 2.1% to $281.7 million in 2026.
• The last three Total Liabilities figures came in at $281.7 million (Q1 2026), $287.7 million (Q4 2025), and $286.4 million (Q3 2025), per Business Quant data.